Search results
Dr. Walensky is currently Principal Investigator and Attending Physician in the Department of Pediatric Oncology at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Professor Pediatrics at Harvard Medical School; and Director of the Harvard/MIT MD-PhD Program.
Loren D. Walensky. Professor of Pediatrics, Dana-Farber Cancer Institute and Harvard Medical School. Verified email at dfci.harvard.edu - Homepage. Chemical Biology Pediatrics Pediatric...
May 1, 2019 · Loren David Walensky, M.D., Ph.D. Design of stapled antimicrobial peptides that are stable, nontoxic and kill antibiotic-resistant bacteria in mice. Authors: Authors: Mourtada R, Herce HD, Yin DJ, Moroco JA, Wales TE, Engen JR, Walensky LD. Targeting BAX to drug death directly.
Loren David Walensky. The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer. Our goal is to develop an arsenal of new compounds-a “chemical toolbox”-to investigate and block protein interactions that cause cancer.
The Walensky laboratory focuses on the chemical biology of deregulated apoptotic and transcriptional pathways in cancer. Our goal is to develop an arsenal of new compounds-a “chemical toolbox”-to investigate and block protein interactions that cause cancer and other diseases.
Walensky is currently Principal Investigator and Attending Physician in the Department of Pediatric Oncology at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Professor Pediatrics at Harvard Medical School; and Director of the Harvard/MIT MD-PhD Program.
Loren D. Walensky's 27 research works with 2,059 citations and 1,323 reads, including: Distinct distribution of specific members of protein 4.1 gene family in the mouse nephron.
